论文部分内容阅读
目的:通过免疫组化分析观察妊娠期乳腺癌患者雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体-2(HER-2)表达情况。方法:将茂名市中医院2010年6月至2015年5月收治的30例妊娠期乳腺癌患者设为观察组,将同期收治的30例非妊娠期乳腺癌患者设为对照组,采用免疫组化法检测两组患者病理组织中ER、PR、HER-2的表达情况,并进行对比分析。结果:免疫组化分析结果显示观察组患者ER、PR、HER-2阳性检出率分别为60.0%、63.3%、36.7%,对照组患者ER、PR、HER-2阳性检出率为83.3%、90.0%、43.3%,两组患者ER、PR阳性检出率比较,差异具有统计学意义(P<0.05),两组患者HER-2阳性检比较,差异无统计学意义(P>0.05)。术后随访两组患者3年,观察组患者的病死率为13.3%,与对照组患者的10.0%比较,差异无统计学意义(P>0.05)。结论:妊娠期乳腺癌患者病理组织中ER、PR的阳性表达率较非妊娠期乳腺癌患者低,根据上述指标对患者病情进展情况进行评估存在一定难度。
Objective: To investigate the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2) in patients with breast cancer during pregnancy by immunohistochemistry. Methods: Thirty pregnant women with breast cancer admitted from June 2010 to May 2015 in Maoming City Hospital were enrolled as observation group. Thirty non-pregnant women with breast cancer admitted in the same period were enrolled as control group. Immunized group The levels of ER, PR and HER-2 in the pathological tissues of two groups were detected by the chemiluminescence method and compared. Results: Immunohistochemical analysis showed that the positive rates of ER, PR and HER-2 in the observation group were 60.0%, 63.3% and 36.7% respectively. The positive rates of ER, PR and HER-2 in the control group were 83.3% , 90.0% and 43.3%, respectively. There was no significant difference between the two groups in the positive rate of ER and PR (P0.05) . The postoperative follow-up of two groups of patients for 3 years, the observation group patients mortality was 13.3%, compared with 10.0% of the control group patients, the difference was not statistically significant (P> 0.05). Conclusion: The positive rates of ER and PR in pathological tissues of pregnant women with breast cancer are lower than those in non-pregnant women. According to the above indexes, it is difficult to evaluate the progress of the disease.